943319-70-8 普纳替尼

普纳替尼

英文名称:ponatinib
CAS:

943319-70-8

分子式:C29H27F3N6O
精选商品
  • 化合物简介
  • 基本信息
  • 编号系统
  • 物化性质
  • MSDS
  • 图谱

普纳替尼简介

Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
The United States Food and Drug Administration approved the drug as a candidate in December 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.
In the US it can cost $138,000 a year which has been criticised.

普纳替尼基本信息

中文名称 普纳替尼 英文名称 ponatinib
中文别名

帕纳替尼PONATINIB; 帕纳替尼;

查看更多中文别名
英文别名

Iclusig; PONATINIB; 3-(2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;

查看更多英文别名
CAS号 943319-70-8 分子式 C29H27F3N6O
分子量 532.55900 精确质量 532.22000
PSA 65.77000 LOGP 4.40480

普纳替尼编号系统

MDL号 MFCD17215203

普纳替尼物化性质

密度:
1.292 g/cm3
SDS 1.0 中文 展开
SDS 1.0 英文 展开
1H NMR : Predict展开

核磁图谱 1H NMR : Predict

收起
查看更多
普纳替尼
CAS号:943319-70-8 分子式:C29H27F3N6O 分子量:532.55900

化工圈APP

二维码

微信公众号

二维码

购物车

不要让您的购物车空着哦,买试剂买原料
如果您已添加过宝贝,那就赶紧登录查看吧

投诉建议

  • 咨询类别
  • 问题描述
  • 联系人电话
  • 联系人